Education

The George Washington University Law School, J.D.

University of Michigan, B.A., with distinction

Bar Admissions

Virginia
District of Columbia

  • Add to address book
  • Printer friendly
  • Email this page to a friend
  • Generate a PDF version of this page

Michael J. Werner

Partner
Washington, D.C.
t: 202-419-2515

Michael Werner has more than 25 years of healthcare law, lobbying, policy development and regulatory experience in Washington. He focuses on issues affecting biotechnology and pharmaceutical companies, researchers and research institutions, physicians and patients. His specific areas of knowledge include FDA drug/biologic regulations; reimbursement strategy and issues; FDA and NIH oversight of clinical trials including registries and reporting of trial results; approval and marketing of orphan drugs; stem cell research and regulation of cell therapy and regenerative medicine products; as well as conflicts of interest and other bioethics issues arising from research and uses of new technologies.

Mr. Werner is the co-founder and Executive Director of the Alliance for Regenerative Medicine, a Washington, DC-based organization whose mission is to advocate for federal funding, regulatory and reimbursement policies that will advance regenerative medicine research and product development.

Before joining Holland & Knight, he was president of The Werner Group, a Washington, D.C.-based firm that provided lobbying, regulatory, and bioethics consulting services for biotechnology and pharmaceutical companies, physicians, health plans, investors, and patient advocacy groups. Prior to founding The Werner Group, he was chief of policy for the Biotechnology Industry Organization (BIO), representing over 1000 biotechnology companies in the U.S. and other countries. In that role, he was responsible for virtually all major issues affecting biotech companies including: drug evaluation and review by FDA; CMS policies and reimbursement, Medicare, intellectual property, stem cell research and other sensitive bioethics issues.

Mr. Werner is also a founding member of the Board of Directors of the Coalition for the Advancement of Medical Research (CAMR), an organization of over 100 nationally-recognized patient organizations, universities, scientific societies, foundations, and individuals that advocates for the advancement of breakthrough research and technologies in stem cell research and related fields.

Before BIO, he spent six years as counsel for legislation and policy for the American College of Physicians where he performed legal analysis, and congressional and regulatory advocacy on such issues as Medicare reform; liability reform; integration and delivery system re-structuring; quality improvement; and end of life care.

Mr. Werner was senior healthcare advisor to U.S. Senate Majority Leader George Mitchell, a congressional investigator for the U.S. Senate Special Committee on Aging, and senior advisor to Maryland Governor William Donald Schaefer.

He is a heavily sought-after speaker for meetings and conferences, and the author of over 40 published articles. Mr. Werner is a frequent media commentator and has appeared in The Wall Street Journal, Science, Scientific American, The Washington Post, BIOWorld, Congressional Quarterly, and The Baltimore Sun, as well as on many TV and radio news programs.

Memberships

  • Biomedical Engineering Society, Ethics Committee
  • Coalition for the Advancement of Medical Research, Board of Directors
  • University of Michigan Alumni Club of Washington, DC, Board of Directors

Court Admissions

  • Supreme Court of Virginia

Speaking Engagements

  • "Regulatory Issues Affecting Commercialization of Regenerative Medicine Products," "Developing Cell Potency Assay Standards for Industry," and "Patients, Physicians and Phonies: Resetting Public Expectations to Lever Patient Advocacy for RM," Stem Cells USA & Regenerative Medicine Congress, Boston, MA, September 15, 2011
  • "Synthetic Biology: Federal Regulations to Ensure Safe and Ethical Use," BIO International Convention, Washington, D.C., June 28, 2011
  • "Constructing a 'Regulatory Roadmap' to bring Cell Therapy to the Clinic," World Stem Cells & Regenerative Medicine Congress, London, May 11-13, 2010
  • "Bioethics: Synonymous With Good Business," BIO International Conference, Chicago, IL, May 4, 2010
  • "Regulation, Law and Policy of Cell-Based Therapies," Food and Drug Law Institute, Washington, D.C., April 23, 2010
  • "Bridging: From the Bench to the Bedside" and "Regulatory and Reimbursement Strategies," Translational Regenerative Medicine Forum, Winston-Salem, NC, April 7, 2010
  • "Bioethics and the Biotech Industry," BIOtech Now Podcast, March 26, 2010
  • "U.S. Health Care Reform: Political Perspectives and Commercial Opportunities," Danish-American Business Forum, March 22, 2010
  • "Analyzing the Impact of the Obama Administration’s Healthcare Regime on the Evolution of Priorities for Vaccines," Phacilitate Vaccine Forum, Washington, D.C., January 27, 2010
  • "How Are Regulatory Frameworks and Guidelines for Cell/Gene Therapies and Tissue-Engineered Products Continuing to Evolve?," Phacilitate Cell & Gene Therapy Forum, Washington, D.C., January 26, 2010
  • "What Traditional and Alternative Funding Options Are Now Open to Academics and Companies Seeking to Translate Preclinical Cell/Gene Therapy and Tissue Engineered Product Candidates to Phase IIa and Beyond?," Phacilitate Cell & Gene Therapy Forum, Washington, D.C., January 25, 2010
  • "Michael Werner on the New NIH Stem Cell Guidelines," BIOtech Now Interview with Tracy Krughoff, July 9, 2009
  • "Financial Conflicts of Interest in Medical Research: Problem or Problem of Perception" and "Developing Drugs for Rare Diseases," Bio International Convention, May 18-21 2009
  • Panelist, "Stem Cells: Translation to Clinic," StemConn, March 23-24, 2009
  • "Commercialization of Stem Cell Products," World Stem Cell Summit, Madison, WI, September 23, 2008
  • "Enhancement in Sports: Sports Doping and the New Age of Enhancement," Center for American Progress, August 8, 2008

Published Articles & Books